Ixico Plc

DELRAY BEACH, Fla., Oct. 3, 2024 /PRNewswire/ -- The global clinical trial imaging market is on track to grow from USD 1.42 billion in 2024 to USD 2.07 billion by 2029, with a compound annual growth rate (CAGR) of 7.8%. This growth is driven by increased research and development funding in pharmaceuticals and biotechnology, coupled with a rise in Contract Research Organizations (CROs). However, high costs associated with imaging equipment and services may hinder expansion. The services segment currently dominates the market, reflecting a demand for comprehensive clinical study support, while computed tomography holds the largest share among imaging modalities. North America leads in market share due to its advanced R&D and aging population. Emerging economies like India and China also present significant growth opportunities, especially as they attract investment in clinical trials. Key players in the market include ICON plc, Clario, and IXICO, which are innovating to enhance clinical trial efficiencies. Overall, the clinical trial imaging market is poised for substantial growth driven by rising drug development demands and advancements in imaging technologies. MarketsandMarkets Logo

CHICAGO, Aug. 18, 2023 /PRNewswire/ -- In the near future, the Clinical Trial Imaging industry is poised to undergo a transformative evolution, driven by rapid advancements in medical imaging technology, data analytics, and regulatory frameworks. Cutting-edge imaging modalities such as functional MRI, molecular imaging, and advanced PET-CT scans will enable researchers to delve deeper into the intricacies of disease progression and treatment response, providing more nuanced and personalized insights. Integration of artificial intelligence and machine learning algorithms will streamline image analysis, facilitating quicker and more accurate diagnoses, patient stratification, and endpoint determination. Additionally, seamless collaboration between pharmaceutical companies, research institutions, and imaging facilities, coupled with standardized protocols, will enhance data sharing and accelerate clinical trial timelines. However, this expansion will also bring challenges in terms of data security, protocol harmonization, and ensuring the reliability of novel imaging techniques. In essence, the Clinical Trial Imaging industry's imminent future promises to revolutionize the landscape of medical research, enhancing the efficiency and effectiveness of drug development while ultimately benefiting patient outcomes. Clinical Trial Imaging Market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $1.9 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising expenditures in research and development, the expansion of the pharmaceutical and biotechnology sectors, and the proliferation of Contract Research Organizations (CROs) constitute several additional factors. Emerging economies like China, India, and Japan present attractive prospects for stakeholders engaged in the clinical trial imaging market. Download an Illustrative overview: Browse in-depth TOC on "Clinical Trial Imaging Market" 111 - Tables 38 - Figures 179 - Pages Clinical Trial Imaging Market Scope: The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022 Based on product, the clinical trial imaging market is segmented into services and software. In 2022, services accounted for the largest share of the global clinical trial imaging market. The large share of this segment can primarily be attributed to the high cost of imaging equipment, which has driven the outsourcing of imaging clinical trials by pharmaceutical, biotechnology, and medical device manufacturers to service providers. Positron emission tomography segment to register the highest growth rate during the forecast period The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities. In 2022, the positron emission tomography segment accounted for the highest growth rate. Technological expansions and the introduction of new tracers for cardiology, oncology, and neurology applications are expected to support the adoption of PET systems in clinical trial settings. The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022 Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area. In 2022, the oncology segment accounted for the largest share of the clinical trial imaging market. The dominant portion of this segment's market share can be chiefly attributed to the extensive volume of oncology-related clinical trials, driven by the global increase in cancer incidence. North America is the largest regional market for clinical trial imaging market The global clinical trial imaging market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the clinical trial imaging market. The large share of this region can be attributed to the growing cutting-edge medical technologies, a mounting count of pharmaceutical and biotechnology enterprises, and substantial governmental investments in clinical research and development. Request Sample Pages: Clinical Trial Imaging Market Dynamics: Drivers: Increasing R&D spending Growth of pharmaceutical and biotechnology industries Increasing number of CROs Restraints: High implementation cost of imaging systems Opportunities: Growth opportunities in emerging economies Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals Challenges: High cost of clinical trials Key Market Players: The major players operating in this market are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US). Recent Developments: In March 2023, ICON Plc. (Ireland) announced a strategic partnership with LEO Pharma (Denmark) to scale clinical trial execution that is patient-centric and cost effective, and which will support the company's overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry. In March 2023, Clario (US), announced the launch of a cutting-edge cloud-based image viewer tool for sponsors and contract research organizations to view images related to their clinical trials. In May 2021 IXICO Plc. (UK) signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract. Get 10% Free Customization on this Report: Clinical Trial Imaging Market Advantages: Enhanced Decision Making: Imaging technologies allow researchers and clinicians to visualize biological processes and disease progression in real-time. This enables more informed decision-making during clinical trials by providing objective and quantifiable data on treatment efficacy and safety. Early Endpoint Identification: Imaging enables the identification of early treatment responses and disease progression markers, enabling the early determination of trial endpoints. This leads to quicker assessment of treatment outcomes and potential for adaptive trial designs. Patient-Centric Approach: Imaging modalities like PET scans, MRIs, and CT scans provide a non-invasive way to monitor patient health, reducing the need for invasive procedures. This patient-centric approach improves participant comfort and compliance in clinical trials. Personalized Medicine: Advanced imaging techniques facilitate the identification of patient subgroups that respond better to specific treatments. This leads to the development of targeted therapies, enhancing treatment effectiveness and minimizing adverse effects. Efficient Drug Development: Imaging accelerates drug development by providing insights into a drug's mechanism of action and its impact on disease pathways. This reduces the time and costs associated with traditional trial endpoints, contributing to faster market entry for new drugs. Objective Quantification: Imaging offers objective measurements of treatment effects, reducing subjectivity in data interpretation. This improves the robustness and credibility of trial results, enhancing the likelihood of regulatory approval. Global Collaboration: Digital imaging technology allows real-time sharing of data across geographical boundaries, facilitating collaboration among researchers, clinicians, and regulatory agencies. This leads to standardized protocols and increased harmonization across clinical trials. Regulatory Compliance: Well-established imaging techniques adhere to rigorous regulatory standards, ensuring the safety and ethical considerations of participants. This instills confidence in trial outcomes and supports regulatory approval processes. Longitudinal Monitoring: Imaging enables researchers to track disease progression and treatment response over time, providing insights into the long-term effects of interventions. This information is crucial for understanding chronic diseases and evaluating treatment durability. Translational Research: Clinical trial imaging bridges the gap between preclinical research and human studies, allowing researchers to validate findings in real-world patient populations. This aids in the translation of promising preclinical discoveries into effective clinical interventions. In summary, the advantages of the Clinical Trial Imaging market lie in its ability to provide objective, precise, and timely data, enhancing the efficiency and success rate of drug development while ultimately benefiting patient care and medical advancements. Related Reports: CRO Services Market - Global Forecasts to 2028 Mice Model Market - Global Forecasts to 2028 Clinical Trial Supplies Market - Global Forecasts to 2028 Contrast Media Market - Global Forecasts to 2027 Diagnostic Imaging Market - Global Forecasts to 2026 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets

DUBLIN, June 14, 2022 /PRNewswire/ -- The "Global Diagnostics Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 3,200 Diagnostics deals. The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Diagnostics agreements announced in the life sciences since 2015. The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals. The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 3,200 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. A comprehensive series of appendices is provided organized by Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostics partnering and dealmaking since 2015. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostics technologies and products. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: Companion Diagnostics Imaging CT Endoscope Molecular and nuclear MRI Ultrasound X-ray PET SPECT Angiography Fluroscopy Mammography In vitro diagnostics Molecular diagnostics Prognostics Theranostics Key benefits Global Diagnostics Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits: In-depth understanding of Diagnostics deal trends since 2015 Access to headline, upfront, milestone and royalty data Detailed access to actual Diagnostics contracts entered into by leading biopharma companies Identify most active Diagnostics dealmakers since 2015 Insight into terms included in a Diagnostics partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies In Global Diagnostics Partnering Terms and Agreements 2015-2022, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Diagnostics dealmaking 2.1. Introduction 2.2. Diagnostics partnering over the years 2.3. Most active Diagnostics dealmakers 2.4. Diagnostics partnering by deal type 2.5. Diagnostics partnering by therapy area 2.6. Deal terms for Diagnostics partnering 2.6.1 Diagnostics partnering headline values 2.6.2 Diagnostics deal upfront payments 2.6.3 Diagnostics deal milestone payments 2.6.4 Diagnostics royalty rates Chapter 3 - Leading Diagnostics deals 3.1. Introduction 3.2. Top Diagnostics deals by value Chapter 4 - Most active Diagnostics dealmakers 4.1. Introduction 4.2. Most active Diagnostics dealmakers 4.3. Most active Diagnostics partnering company profiles Chapter 5 - Diagnostics contracts dealmaking directory 5.1. Introduction 5.2. Diagnostics contracts dealmaking directory Chapter 6 - Diagnostics dealmaking by technology type Appendices Appendix 1 - Diagnostics deals by company A-Z Appendix 2 - Diagnostics deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Diagnostics deals by deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Litigation Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination Warranty Appendix 4 - Diagnostics deals by therapy area Appendix 5 -Deal type definitions Appendix 6 - Further reading on dealmaking Companies Mentioned IBA IBM iCAD Icon IDS IDx Imbio Imec IMI IMRIS IPMD IQ-AI ITEL Item ITOCO Itus IXICO KEW Kore Lab21 LGC Image Analysis Great Basin Scientific Cosmo Bio Anpac Bio-Medical Science AmCad BioMed Canon BioMedical Cenix BioScience InGen BioSciences Array Biopharma Bliss Biopharmaceutical Agena Bioscience Crown Bioscience Akers Biosciences Akoya Biosciences Alume Biosciences Anixa Biosciences Arbor Biosciences For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets